Title | Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MCarmela, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC |
Corporate Authors | Genetic FTD Initiative(GENFI), Alzheimer’s Disease Neuroimaging Initiative(ADNI) |
Journal | Nat Commun |
Volume | 9 |
Issue | 1 |
Pagination | 4273 |
Date Published | 2018 10 15 |
ISSN | 2041-1723 |
Keywords | Alzheimer Disease, Frontotemporal Dementia, Genotype, Humans, Models, Neurological, Neurodegenerative Diseases, Phenotype, Reproducibility of Results, Time Factors |
Abstract | The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. Here we introduce a machine-learning technique-Subtype and Stage Inference (SuStaIn)-able to uncover data-driven disease phenotypes with distinct temporal progression patterns, from widely available cross-sectional patient studies. Results from imaging studies in two neurodegenerative diseases reveal subgroups and their distinct trajectories of regional neurodegeneration. In genetic frontotemporal dementia, SuStaIn identifies genotypes from imaging alone, validating its ability to identify subtypes; further the technique reveals within-genotype heterogeneity. In Alzheimer's disease, SuStaIn uncovers three subtypes, uniquely characterising their temporal complexity. SuStaIn provides fine-grained patient stratification, which substantially enhances the ability to predict conversion between diagnostic categories over standard models that ignore subtype (p = 7.18 × 10) or temporal stage (p = 3.96 × 10). SuStaIn offers new promise for enabling disease subtype discovery and precision medicine. |
DOI | 10.1038/s41467-018-05892-0 |
Alternate Journal | Nat Commun |
PubMed ID | 30323170 |
PubMed Central ID | PMC6189176 |
Grant List | MC_UU_00005/12 / MRC_ / Medical Research Council / United Kingdom U01 AG024904 / AG / NIA NIH HHS / United States MC_UU_00024/1 / MRC_ / Medical Research Council / United Kingdom MR/M008525/1 / MRC_ / Medical Research Council / United Kingdom MR/M023664/1 / MRC_ / Medical Research Council / United Kingdom MR/M009041/1 / MRC_ / Medical Research Council / United Kingdom MR/M009106/1 / MRC_ / Medical Research Council / United Kingdom MC_U105597119 / MRC_ / Medical Research Council / United Kingdom / / Wellcome Trust / United Kingdom P30 AG010129 / AG / NIA NIH HHS / United States MR/M024873/1 / MRC_ / Medical Research Council / United Kingdom MR/J009482/1 / MRC_ / Medical Research Council / United Kingdom |
Related Institute:
Brain Health Imaging Institute (BHII)